Naval Medical Research Center, Silver Spring, Maryland, USA.
Infect Immun. 2010 Apr;78(4):1750-9. doi: 10.1128/IAI.01021-09. Epub 2010 Jan 19.
A human Campylobacter jejuni infection model provided controlled exposure to assess vaccine efficacy and investigate protective immunity for this important diarrheal pathogen. A well-characterized outbreak strain, C. jejuni 81-176, was investigated using a volunteer experimental infection model to evaluate the dose range and duration of protection. Healthy Campylobacter-seronegative adults received C. jejuni strain 81-176 via oral inoculation of 10(5), 10(7), or 10(9) CFU (5 adults/dose), which was followed by clinical and immunological monitoring. Based on dose range clinical outcomes, the 10(9)-CFU dose (n = 31) was used to assess homologous protection at 28 to 49 days (short-term veterans [STV]; n = 8) or 1 year (long-term veterans [LTV]; n = 7) after primary infection. An illness dose effect was observed for naïve subjects (with lower doses, 40 to 60% of the subjects were ill; with the 10(9)-CFU dose, 92% of the subjects were ill) along with complete protection for the STV group and attenuated illness for the LTV group (57%). Partial resistance to colonization was seen in STV (25% of the subjects were not infected; 3-log-lower maximum excretion level). Systemic and mucosal immune responses were robust in naïve subjects irrespective of the dose or the severity of illness. In contrast, in STV there was a lack of circulating antibody-secreting cells (ASC), reflecting the local mucosal effector responses. LTV exhibited comparable ASC responses to primary infection, and anamnestic fecal IgA responses likely contributed to self-resolving illness prior to antibiotic treatment. Campylobacter antigen-dependent production of gamma interferon by peripheral blood mononuclear cells was strongly associated with protection from illness, supporting the hypothesis that TH1 polarization has a primary role in acquired immunity to C. jejuni. This study revealed a C. jejuni dose-related increase in campylobacteriosis rates, evidence of complete short-term protection that waned with time, and immune response patterns associated with protection.
人类空肠弯曲菌感染模型提供了受控暴露,以评估疫苗的功效,并研究这种重要的腹泻病原体的保护性免疫。使用志愿者实验感染模型研究了一种特征明确的暴发菌株,空肠弯曲菌 81-176,以评估剂量范围和保护持续时间。健康的空肠弯曲菌血清阴性成年人通过口服接种 10(5)、10(7)或 10(9)CFU(每种剂量 5 名成年人)感染空肠弯曲菌 81-176,随后进行临床和免疫学监测。基于剂量范围的临床结果,使用 10(9)-CFU 剂量(n = 31)评估同源保护,在初次感染后 28 至 49 天(短期退伍军人 [STV];n = 8)或 1 年(长期退伍军人 [LTV];n = 7)。在未感染的受试者中观察到疾病剂量效应(低剂量时,40%至 60%的受试者患病;使用 10(9)-CFU 剂量时,92%的受试者患病),STV 组完全保护,LTV 组疾病减轻(57%)。STV 组观察到定植的部分抗性(25%的受试者未感染;最大排泄水平低 3 个对数级)。无论剂量或疾病严重程度如何,系统和黏膜免疫反应在未感染的受试者中均很强。相比之下,在 STV 中,循环抗体分泌细胞(ASC)缺乏,反映了局部黏膜效应反应。LTV 表现出与初次感染相当的 ASC 反应,在抗生素治疗之前,自身粪便 IgA 反应可能有助于自行缓解疾病。外周血单核细胞对空肠弯曲菌抗原的依赖性产生γ干扰素与免于患病强烈相关,支持 TH1 极化在空肠弯曲菌获得性免疫中起主要作用的假说。本研究揭示了空肠弯曲菌感染率与空肠弯曲菌剂量呈正相关,存在短期完全保护的证据,但随着时间的推移会减弱,以及与保护相关的免疫反应模式。